Triple negative breast cancer treatment options and limitations: future outlook
O Obidiro, G Battogtokh, EO Akala - Pharmaceutics, 2023 - mdpi.com
Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …
Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies
GK Gupta, AL Collier, D Lee, RA Hoefer, V Zheleva… - Cancers, 2020 - mdpi.com
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Background We aimed to report on long-term outcomes of patients with small, node-
negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and …
negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and …
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab
emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded …
emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded …
Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address
treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive …
treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive …
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease
for which there is no targeted therapy,,. BET bromodomain inhibitors, which have shown …
for which there is no targeted therapy,,. BET bromodomain inhibitors, which have shown …
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang… - … England Journal of …, 2015 - Mass Medical Soc
Background No single standard treatment exists for patients with small, node-negative,
human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because …
human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because …
Triple-negative breast cancer: who should receive neoadjuvant chemotherapy?
LN Chaudhary, KH Wilkinson… - Surgical Oncology …, 2018 - surgonc.theclinics.com
With advances in genetic studies, breast cancer has been identified as a heterogeneous
disease with distinct subtypes that respond variably to different therapies. The concept of …
disease with distinct subtypes that respond variably to different therapies. The concept of …
[HTML][HTML] Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter …
D Mavroudis, E Saloustros, N Malamos, S Kakolyris… - Annals of …, 2015 - Elsevier
Background Adjuvant trastuzumab in combination with chemotherapy improves survival of
women with HER2-positive early breast cancer. In this study, we compared 12 versus 6 …
women with HER2-positive early breast cancer. In this study, we compared 12 versus 6 …
ER+/HER2+ breast cancer has different metastatic patterns and better survival than ER−/HER2+ breast cancer
Background Human epidermal growth factor receptor 2–positive (HER2+) breast cancer is
generally treated with HER2-targeted therapy combined with chemotherapy. Patients with …
generally treated with HER2-targeted therapy combined with chemotherapy. Patients with …